Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
Introduction: The choice of BCR-ABL1 tyrosine kinase inhibitors (TKI) for the first line of therapy (LOT) for chronic-phase chronic myeloid leukemia (CML) is tailored to disease risk and patient characteristics like comorbidities, which become more prevalent with age. However, contemporary evaluatio...
Guardado en:
Autores principales: | Rory M. Shallis, Rong Wang, Jan P. Bewersdorf, Amer M. Zeidan, Amy J. Davidoff, Scott F. Huntington, Nikolai A. Podoltsev, Xiaomei Ma |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f9cb5ac8d0f14aa8b6c4e76d443c97fb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
por: Mohammad Abu-Tineh, et al.
Publicado: (2021) -
NEW ADVANCES IN PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Özlem Tüfekçi
Publicado: (2021) -
EXPERIENCE OF GLASDEGIB IN PATIENTS WITH ELDERLY ACUTE MYELOID LEUKEMIA
por: Nanişe Gizem FENER, et al.
Publicado: (2021) -
Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias
por: Thomas X
Publicado: (2012) -
PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
por: Serap Karaman, et al.
Publicado: (2021)